How Will Deep Brain Stimulation Affect Neurological and Psychiatric Drug Markets?

Decision Resources, Inc, August 2006, Pages: 26

Deep brain stimulation (DBS) is currently approved only to treat Parkinson’s disease and Parkinson-like symptoms; however, clinical trials are under way for DBS in several other neurological and psychiatric disorders. As these surgical interventions gain acceptance in the face of conventional therapies’ shortcomings in severely affected patients, opportunities are emerging for such devices, used both alone and in conjunction with existing drug regimens.

Get the Answers You Need to Shape Your Strategy
Currently, DBS is approved only for Parkinsonism. For what other indications is DBS being investigated? What advantages does DBS offer to treat these indications? What potential exists for DBS in these indications?
The risk factors associated with DBS have made it a last-resort therapy for most indications.
How competitive will DBS be with conventional drug therapies? In which indications will it stand out? Will DBS ever be used as an early therapy, in any indication?
Medtronic is the only company to have an approved device for DBS, although several companies have devices in development for other indications. Which of the companies developing DBS devices is best positioned to succeed in these new markets? What innovations must these companies provide to ensure success? Which company is poised to collaborate with drug makers in creating a viable combination therapy?

Scope of this Report:

- Therapeutic overview: medical and regulatory landscape for DBS.
- Indications covered: Parkinson’s disease, epilepsy, obsessive-compulsive disorder, depression, and headaches including migraines.
- Companies developing DBS devices: profi les of companies developing devices for the DBS market.
- Drug markets: impact of DBS therapy on indication-specifi c drug markets.
- Market outlook: considerations for the DBS device market over 2005-2015 including cost and patient share and physician opinion.

Executive Summary
Strategic Implications
Stakeholder Implications
Introduction
Overview of DBS
DBS for Specific Therapeutic Areas
Parkinson’s Disease
Epilepsy
Psychiatric Disorders: OCD and Depression
Headaches
Companies Developing DBS Systems
Medtronic
NeuroPace
Cyberonics
Boston Scientific
Medtrode
Advanced Neuromodulation Systems
Impact of DBS on Drug Markets
Market Implications
DBS and the PD Market
DBS and the Epilepsy Market
DBS and the Psychiatric Markets
DBS and the Headache Market
Codevelopment of Pharmacological Agents and DBS
Outlook for DBS in the Marketplace
Bibliography

Tables
1 Brain Regions Implicated in Epileptic Seizures
2 Companies Developing DBS Devices

Figures
1 Regions of the Brain Targeted for Deep Brain Stimulation
2 Schematic of Deep Brain Stimulation
3 Growth of DBS Procedures, by Indication, 2005-2015

- Advanced
- Neuromodulation Systems
- Aguettant
- Boston Scientifi c
- Britannia Pharmaceuticals
- Cephalon
- Ceregene
- Chiesi Farmaceutici
- Cyberonics
- D-Pharm
- Medtronic
- Medtrode
- Neopharma
- Neurologix
- Neuronetics
- NeuroPace
- Schering AG
- Vernalis

Customers who bought this item also bought

• Neurostimulation - Advanced Technologies and Global Market (2009 - 2014)
• Neuroprotection - Drugs, Markets and Companies
• Gene Therapy - Technologies, Markets and Companies
• 03 - 2012 Emerging Medical Technologies Spotlight: A Report of Investment & Partnering Opportunities
• Biomarkers - Technologies, Markets and Companies
• Cell Therapy - Technologies, Markets and Companies
• Strategic Development of Neural Stem & Progenitor Cell Products
• Dried Blood Spots Part 1
• 01 - 2012 Emerging Medical Technologies Spotlight: A Report of Investment & Partnering Opportunities
• Nanobiotechnology Applications, Markets and Companies